Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT

TY - JOUR

T1 - Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT

AU - Sanz, Jaime

AU - Labopin, Myriam

AU - Blaise, Didier

AU - Raiola, Anna Maria

AU - Busca, Alessandro

AU - Vydra, Jan

AU - Tischer, Johanna

AU - Chevallier, Patrice

AU - Bramanti, Stefania

AU - Fanin, Renato

AU - Socié, Gerard

AU - Forcade, Edouard

AU - Kröger, Nicolaus

AU - Koc, Yener

AU - Itälä-Remes, Maija

AU - Zecca, Marco

AU - Nagler, Arnon

AU - Brissot, Eolia

AU - Spyridonidis, Alexandros

AU - Bazarbachi, Ali

AU - Giebel, Sebastian

AU - Piemontese, Simona

AU - Mohty, Mohamad

AU - Ciceri, Fabio

N1 - Copyright © 2024 American Society of Hematology.

PY - 2024/5/28

Y1 - 2024/5/28

N2 - There is a paucity of information to guide the selection of the most suitable donor in haploidentical (Haplo) hematopoietic stem cell transplantation (HSCT). For this reason, from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we conducted a retrospective analysis to evaluate the impact of Haplo donor characteristics on outcomes in patients with acute myeloid leukemia (AML) who received graft-versus-host disease prophylaxis with posttransplant cyclophosphamide (PTCy). The primary end point was graft-versus-host disease (GVHD)-free and relapse-free survival (GRFS). Overall, 2200 patients were included. The median age of donors was 37 years (range, 8-71); 820 (37%) were females, including 458 (21%) who were used for male recipients. In addition, 1631 donors (74%) donated peripheral blood (PB). Multivariable analysis identified certain donor-related risk factors with a detrimental impact on transplant outcomes. The use of PB, older donors' ages (>37 years), and female donors to male recipients negatively affected GRFS. Donor's age and female donor-to-male recipient combination also affected nonrelapse mortality, leukemia-free survival, and overall survival. In conclusion, donor-related variables significantly influence outcomes in patients with AML after Haplo-HSCT with PTCy. When possible, younger donors and male donors for male recipients should be prioritized. The use of bone marrow can additionally prevent GVHD.

AB - There is a paucity of information to guide the selection of the most suitable donor in haploidentical (Haplo) hematopoietic stem cell transplantation (HSCT). For this reason, from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we conducted a retrospective analysis to evaluate the impact of Haplo donor characteristics on outcomes in patients with acute myeloid leukemia (AML) who received graft-versus-host disease prophylaxis with posttransplant cyclophosphamide (PTCy). The primary end point was graft-versus-host disease (GVHD)-free and relapse-free survival (GRFS). Overall, 2200 patients were included. The median age of donors was 37 years (range, 8-71); 820 (37%) were females, including 458 (21%) who were used for male recipients. In addition, 1631 donors (74%) donated peripheral blood (PB). Multivariable analysis identified certain donor-related risk factors with a detrimental impact on transplant outcomes. The use of PB, older donors' ages (>37 years), and female donors to male recipients negatively affected GRFS. Donor's age and female donor-to-male recipient combination also affected nonrelapse mortality, leukemia-free survival, and overall survival. In conclusion, donor-related variables significantly influence outcomes in patients with AML after Haplo-HSCT with PTCy. When possible, younger donors and male donors for male recipients should be prioritized. The use of bone marrow can additionally prevent GVHD.

U2 - 10.1182/bloodadvances.2023012133

DO - 10.1182/bloodadvances.2023012133

M3 - SCORING: Journal article

C2 - 38429091

VL - 8

SP - 2332

EP - 2341

JO - BLOOD ADV

JF - BLOOD ADV

SN - 2473-9529

IS - 10

ER -